Department of Community Medicine & School of Public Health, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Department of Health Economics, Indian Council of Medical Research-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India.
Indian J Med Res. 2023 Jun;157(6):498-508. doi: 10.4103/ijmr.IJMR_389_20.
BACKGROUND & OBJECTIVES: The Government of India has initiated a population based screening (PBS) for noncommunicable diseases (NCDs). A health technology assessment agency in India commissioned a study to assess the cost-effectiveness of screening diabetes and hypertension. The present study was undertaken to estimate the cost of PBS for Type II diabetes and hypertension. Second, out-of-pocket expenditure (OOPE) for outpatient care and health-related quality of life (HRQoL) among diabetes and hypertension patients were estimated.
Economic cost of PBS of diabetes and hypertension was assessed using micro-costing methodology from a health system perspective in two States. A total of 165 outpatients with diabetes, 300 with hypertension and 497 with both were recruited to collect data on OOPE and HRQoL.
On coverage of 50 per cent, the PBS of diabetes and hypertension incurred a cost of ₹ 45.2 per person screened. The mean OOPE on outpatient consultation for a patient with diabetes, hypertension and both diabetes and hypertension was ₹ 4381 (95% confidence interval [CI]: 3786-4976), ₹ 1427 (95% CI: 1278-1576) and ₹ 3932 (95% CI: 3614-4250), respectively. Catastrophic health expenditure was incurred by 20, 1.3 and 14.8 per cent of patients with diabetes, hypertension and both diabetes and hypertension, respectively. The mean HRQoL score of patients with diabetes, hypertension and both was 0.76 (95% CI: 0.72-0.8), 0.89 (95% CI: 0.87-0.91) and 0.68 (95% CI: 0.66-0.7), respectively.
INTERPRETATIONS & CONCLUSIONS: The findings of our study are useful for assessing cost-effectiveness of screening strategies for diabetes and hypertension.
印度政府已经启动了一项基于人群的非传染性疾病(NCDs)筛查(PBS)。印度的一个卫生技术评估机构委托进行了一项研究,以评估筛查糖尿病和高血压的成本效益。本研究旨在估计 II 型糖尿病和高血压的 PBS 成本。其次,估计了糖尿病和高血压患者的门诊护理和健康相关生活质量(HRQoL)的自付费用(OOPE)。
从卫生系统的角度出发,采用微观成本法评估了两个州的糖尿病和高血压 PBS 的经济成本。共招募了 165 名糖尿病门诊患者、300 名高血压患者和 497 名同时患有糖尿病和高血压的患者,以收集 OOPE 和 HRQoL 数据。
在覆盖 50%的情况下,糖尿病和高血压的 PBS 筛查每人花费 45.2 卢比。糖尿病、高血压和同时患有糖尿病和高血压的患者门诊咨询的平均 OOPE 分别为 4381 卢比(95%置信区间[CI]:3786-4976)、1427 卢比(95% CI:1278-1576)和 3932 卢比(95% CI:3614-4250)。分别有 20%、1.3%和 14.8%的糖尿病、高血压和同时患有糖尿病和高血压的患者发生灾难性医疗支出。糖尿病、高血压和同时患有糖尿病和高血压的患者的平均 HRQoL 评分分别为 0.76(95% CI:0.72-0.8)、0.89(95% CI:0.87-0.91)和 0.68(95% CI:0.66-0.7)。
我们研究的结果有助于评估糖尿病和高血压筛查策略的成本效益。